45062026 Q3PrimeIFRS

Sumitomo Pharma (4506) FY2026 Q3 Earnings Report

For FY2026 Q3, revenue came to ¥347.7B (+18.6% year on year) and operating income ¥109.8B (+730.0%). The segment drivers and cash flow follow.

Sumitomo Pharma Co.,Ltd.

January 30, 2026

Pharmaceutical

Theoretical share value trend (reference)

JPY per share

Base scenarioBear–bull range

These are mechanically computed values based on a residual income model. They are not a forecast of market prices or a recommendation of any investment action, and do not predict or guarantee future share prices. Historical values are computed retrospectively using current guidance-achievement statistics.

Table of Contents

Quick View

Metric	Current	Prior	YoY
Revenue	¥3477.5B	¥2931.8B	+18.6%
Operating Income	¥1097.7B	¥132.3B	+730.0%
Profit Before Tax	¥1015.4B	¥240.3B	+322.6%
Net Income	¥1076.8B	¥212.2B	+407.4%
ROE	37.3%	12.5%	-

Sumitomo Pharma (4506) FY2026 Q3 Earnings Report

Theoretical share value trend (reference)

Quick View

Executive Summary

Performance Drivers

Segment Analysis

Key Metrics

Cash Flow Analysis

Earnings Quality

Guidance Update

Shareholder Returns

Catalysts

Industry Benchmark (Reference - Proprietary Data)

Risk Factors

Key Takeaways from Earnings

Theoretical share value trend (reference)